Session information—March 13, 2025
Topic
'Primary Immunodeficiencies in Pediatric Hematooncology Practice.'
Speaker details
Camilla Visconti (speaker)
Dr Camilla Visconti is a final-year fellow in the Pediatric Immunology and BMT Unit at San Raffaele Hospital in Milan, where she manages children with inborn errors of immunity. Her responsibilities include:
- Conducting outpatient evaluations
- Providing inpatient care for hematopoietic stem cell transplantation (HSCT) and related complications
- Overseeing post-discharge follow-up
Dr Visconti is also actively involved in advanced therapeutic approaches such as gene therapy. Currently, she is spending six months at Great Ormond Street Hospital in London, further advancing her expertise in pediatric immunology.
Additionally, she is participating in a multicenter research project to expand the genetic diagnosis of unsolved primary immunodeficiency cases and evaluate long-term outcomes in treated versus untreated patients.
Andrew V. Gennery (expert)
Andrew Gennery is Professor in Pediatric Immunology and HSCT at Newcastle University and an Honorary Consultant for the Northern National HSCT Unit for IEI at Great North Children’s Hospital, Newcastle. He spent a year working at the Necker Hospital in Paris, where he was involved in the discovery of cytidine deaminase.
His research interests include immunoreconstitution following HSCT for IEI, long-term outcomes of transplantation for IEI, and appropriate treatment of DNA repair disorders. He has established ECP for the treatment of pediatric GvHD and discovered mechanistic insights relating to the ECP mode of action.
Prof Gennery is a member of ESID and EBMT and recently chaired the ESID/EBMT IEWP, ESID CWP, ERN-RITA Guidelines Working Party, CIBMTR PID IEM, and other NMMD Working Committee. He has published over 430 papers on primary immunodeficiency, co-authored multi-center publications on outcomes of cohorts of children with IEI following HSCT, and contributed relevant chapters in major textbooks.
Prof Gennery is the clinical lead for the SCID NBS pilot in England.
Back